United States: The World Health Organization and pharmaceutical company Eli Lilly and Co. are cautioning the public about fraudulent replications of well-known diabetic and weight-loss medications.
About the News
The WHO announced on Thursday that, since 2022, it has received many reports of phony semaglutide, which is the active component of Novo Nordisk’s Wegovy and Ozempic, from all around the world.
The active component of Lilly’s medications, tirzepatide, which is also the subject of increased online sales and social media posts including fake or compounded forms of the drug, Lilly expressed its “deep concern” in an open letter.
Ac WHO and Eli Lilly advise patients to beware of counterfeit versions of popular weight-loss medications
According to the Indianapolis-based business, tirzepatide is not supplied to internet merchants, wellness centers, compounding pharmacies, or any other legal provider of such medications.
Lilly claimed that using phony copies of its medications, which are often promoted or sold online, is never safe.
Comparable cautions regarding Novo Nordisk’s drugs have been issued in the past.
According to WHO, consumers may safeguard themselves by purchasing pharmaceuticals with prescriptions from authorized medical professionals. The organization advised patients not to purchase the medications from unidentified vendors.
Products advertised as tirzepatide rather than Mounjaro or Zepbound, according to Lilly, were not produced by the pharmaceutical company and did not have FDA approval.
The Howard Hughes Medical Institute’s Science and Educational Media Group provides assistance to the Associated Press Health and Science Department. For all content, the AP is the only source.